Produktinformation
- 1,3,5-Triazine-2,4-diamine, 3,6-dihydro-N2,N2,6-trimethyl-, (6R)-
- 1,3,5-Triazine-2,4-diamine,1,6-dihydro-N,N,6-trimethyl-, (6R)- (9CI)
- 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-N,N,6-trimethyl-, (6R)-
- R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine
- R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]triazin-2-yl)dimethylamine
- Imeglimin
- EMD 387008
Imeglimin is a drug that acts as an antidiabetic agent by targeting energy metabolism. It has been shown to reduce the levels of blood glucose and improve insulin sensitivity in patients with type 2 diabetes. Imeglimin also reduces kidney fibrosis and improves mitochondrial membrane potential, redox potential, and ATP levels in liver cells. Imeglimin has significant interactions with other drugs that affect energy metabolism, such as metformin and phenformin. These drugs should be avoided in patients taking imeglimin to avoid toxic effects on the heart, liver, or kidneys. Imeglimin is metabolized by CYP2C19 into its active form imeglimine.
Chemische Eigenschaften
Technische Anfrage zu: 3D-AGB35165 Imeglimin
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
